Daan Gene Co., Ltd. (SHE:002030)
China · Delayed Price · Currency is CNY 5.37
+0.03 (0.56%)
Oct 23, 2026, 3:04 PM CST
Daan Gene Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 746.91 | 757.66 | 853.02 | 1,181 | 12,046 | 7,664 |
Revenue Growth | -5.60% | -11.18% | -27.77% | -90.20% | 57.17% | 43.49% |
Gross Profit Gross Profit Growth | 99.72 | 89.3 | 225.35 | 379.78 | 8,431 | 5,701 |
Operating Income Operating Income Growth | -274.36 | -541.14 | -711.11 | -356.04 | 6,084 | 3,901 |
Net Income Net Income Growth | -682.6 | -744.38 | -925.17 | 104.66 | 5,412 | 3,618 |
Earnings Per Share EPS Growth | -0.50 | -0.53 | -0.66 | 0.07 | 3.86 | 2.58 |
EPS Growth | - | - | - | -98.19% | 49.59% | 47.74% |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 |
Financial Business Financial Business Growth | 30.38 | 32.43 | 32.04 | 35.9 |
Biological Products and Related Business Biological Products and Related Business Growth | 727.61 | 820.6 | 1,149 | 12,010 |
Offset of Business Offset of Business Growth | -0.32 | - | - | - |
Total Total Growth | 757.66 | 853.02 | 1,181 | 12,046 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 1,436 | 1,488 | 1,794 | 2,400 | 3,561 | 2,559 |
Total Debt Total Debt Growth | 103.7 | 110.48 | 163.94 | 365.83 | 227.8 | 404.06 |
Net Cash (Debt) Net Cash Growth | 1,333 | 1,378 | 1,630 | 2,034 | 3,333 | 2,155 |
Net Cash Growth | 10.92% | -15.46% | -19.86% | -38.98% | 54.66% | 60.03% |
Net Cash Per Share Net Cash Per Share Growth | 0.97 | 0.98 | 1.16 | 1.36 | 2.37 | 1.54 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 355.82 | 319.49 | 300.33 | 780.11 | 4,155 | 3,305 |
Capital Expenditures CapEx Growth | -140.02 | -239 | -174.41 | -572.77 | -1,503 | -658.75 |
Free Cash Flow Free Cash Flow Growth | 215.8 | 80.49 | 125.92 | 207.34 | 2,652 | 2,646 |
Free Cash Flow Growth | 278.88% | -36.08% | -39.27% | -92.18% | 0.24% | 23.08% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 13.35% | 11.79% | 26.42% | 32.16% | 69.99% | 74.39% |
Operating Margin | -36.73% | -71.42% | -83.36% | -30.15% | 50.51% | 50.90% |
Pretax Margin | -89.76% | -99.91% | -125.57% | 9.61% | 52.46% | 53.76% |
Profit Margin | -91.39% | -98.25% | -108.46% | 8.86% | 44.93% | 47.21% |
FCF Margin | 28.89% | 10.62% | 14.76% | 17.56% | 22.02% | 34.52% |
Fiscal Year | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Period Ending | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.015 | 1.750 | 1.110 |
Dividend Per Share Growth | -99.14% | 57.66% | 222.86% |
Dividend Yield | 0.15% | 11.25% | 5.53% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 129.81 | 4.04 | 7.78 |
Forward PE | - | 121.50 | 121.50 | 121.50 | 121.50 | 121.50 |
P/FCF Ratio | 34.92 | 103.92 | 63.31 | 65.52 | 8.23 | 10.64 |
PS Ratio | 10.09 | 11.04 | 9.35 | 11.50 | 1.81 | 3.67 |